PAI-1 – Published Papers Using Affinity Biologicals Products

2011

TE Riehl, L He, L Zheng, S Greco… – … of Thrombosis and …, 2011 – Wiley Online Library
Biotechnology, Santa Cruz, CA, USA), mouse monoclonal anti-COX-2 (610204, 1:500; BD Biosciences, San Jose, CA, USA), rabbit anti-human PGI synthase (SC-20933, 1:200; Santa Cruz) and sheep anti-human PAI-1 (SAPAI-IG, 1:500; Affinity Biologicals, Ontario, Canada).

The antifibrinolytic function of factor XIII is exclusively expressed through

SR Fraser, NA Booth… – 2011 bloodjournal.hematologylibrary.org
isothiocyanate (FITC) labeled fibrinogen was added to pooled normal plasma (PNP) or plasma depleted of FXIII, α2AP, TAFI or PAI (Affinity Biologicals Inc, Canada). or α2AP (Affinity Biologicals).

2009

VG Nielsen – Blood Coagulation & Fibrinolysis, 2009 – journals.lww.com
Blood Coagulation & Fibrinolysis: April 2009 – Volume 20 – Issue 3 – p 191 A second series of experiments with CTI utilized plasminogen activator inhibitor 1 (PAI-1) deficient plasma (<0.01 ng/ml; Affinity Biologicals Inc., Ancaster, Ontario, Canada) that had 0 or 25 μg/ml of potato ..

VG Nielsen, JK Kirklin… – Blood Coagulation & …, 2009 – journals.lww.com
The following immunodepleted plasma types were obtained from Affinity
Biologicals, Inc., Ancaster, Ontario, Canada: plasminogen activator inhibitor type 1 (PAI-1)-deficient plasma (<0.5 ng/ml) with a PT of 14.3 s, an aPTT of 38.5 s, and a fibrinogen ..